Fiscal Year:
2011
Title:
Rare Variant Detection Using Next Genration Sequencing Technology
Agency:
DHS
Contract:
D11PC20117
Award Amount:
$750,000.00
Abstract:
The long-term objective is to develop a rare variant (SNPs) detection pipeline, based on high throughput sequencing (HTS) and
advanced bioinformatics, with the goal of detecting mutations present in ratio as low as 1:1000. To achieve this goal, we propose to: (1)
Develop statistical and computational approaches to evaluate the effects of sequencing platform, target genome, and mapping
algorithm on the accuracy of the rare variant detection. (2) Implement and deliver rare variant detection pipeline. (3) Experimentally
validate the implemented rare variant detection pipeline, culminating a full scale B. anthracis case study. (4) Develop a software
application to automatically acquire defined in task 1 statistical characteristics of errors associated with instruments, platforms, library
preparation protocols, and sequencing chemistry, which can affect the overall accuracy of the rare variant detection.
Rare variant detection is important for prosecution of bioterrorism attacks or attempts. While, the commercial opportunity of the
forensic application is unknown, the commercial applications in clinical diagnostics associated with the detection of drug resistant
variants such as diagnostic test to identify the presence of multi- or extensively- drug resistant tuberculosis present in less than 1
percent of the sample are significant.
Small Business Information at Submission:
Eureka Genomics
750 Alfred Nobel Drive #108 Hercules, CA 94547-1387
EIN/Tax ID:
261320502
DUNS:
N/A
Number of Employees:
Woman-Owned:
No
Minority-Owned:
No
HUBZone-Owned:
No